BiotechTube

C16G2

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dental Caries

Conditions

Dental Caries

Trial Timeline

Jul 1, 2015 → Mar 1, 2016

NCT ID
NCT02509845

About C16G2

C16G2 is a phase 2 stage product being developed by Armata Pharmaceuticals for Dental Caries. The current trial status is completed. This product is registered under clinical trial identifier NCT02509845. Target conditions include Dental Caries.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02509845Phase 2Completed
NCT02254993Phase 2Completed

Competing Products

20 competing products in Dental Caries

See all competitors
ProductCompanyStageHype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
77
Sodium Fluoride DentifriceJohnson & JohnsonPre-clinical
23
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
77
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + PlaceboJohnson & JohnsonPhase 2
52
2 mg nicotine gum + 4 mg nicotine gumJohnson & JohnsonApproved
85
Acetaminophen ER + PlaceboJohnson & JohnsonPhase 2
52
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3
77
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3
77
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
Pregabalin + Alprazolam + PlaceboPfizerPhase 2
51
Prototype (AN0128 Toothpaste)PfizerPhase 1
32
PF-05089771 + PF-05089771 + PF-05089771 + IbuprofenPfizerPhase 2
51
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
51
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3
74
XPF-001 + placeboXenon PharmaceuticalsPhase 2
49
N1539 + placebo + N1539 + N1539 + MotrinAlkermesPhase 2
49
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3
72
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + PlaceboAFT PharmaceuticalsPhase 2
44
Maxigesic 325 + Acetaminophen + Ibuprofen + PlaceboAFT PharmaceuticalsPhase 3
69

Other Products from Armata Pharmaceuticals

C16G2 GelPhase 2
44
AP-PA02Phase 2
44
C16G2 + PlaceboPhase 2
44
C16G2 Varnish + Placebo VarnishPhase 2
44
C16G2 StripPhase 2
44